NeuroPace raises 2025 revenue and gross margin guidance amid record RNS growth and DIXI wind-down [Seeking Alpha]
Neuropace, Inc. (NPCE)
Company Research
Source: Seeking Alpha
CEO Joel Becker stated the third quarter delivered record results for NeuroPace, with total revenue reaching $27.4 million, representing 30% year-over-year growth. Becker indicated, "RNS initial implants drove RNS revenue of $22.6 million and 31% year-over-year growth." He cited broad-based Quick Insights Management expects DIXI revenue to largely disappear after 2025, with core RNS business projected to continue growing at 20%+ annually, supporting raised full-year revenue and margin guidance. NAUTILUS PMA submission is planned before year-end, while pediatric indication timing is delayed beyond 2025; management stresses they are following a real-world evidence approach for pediatrics and see no major new data generation needed. Margins are benefiting from strong RNS sales and the phase-out of lower-margin DIXI sales; sustainability depends on maintaining RNS growth and indication expansion, with 80%+ gross margin expected as DIXI contribution declines. More Trending News
Show less
Read more
Impact Snapshot
Event Time:
NPCE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NPCE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NPCE alerts
High impacting Neuropace, Inc. news events
Weekly update
A roundup of the hottest topics
NPCE
News
- NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual MeetingBusiness Wire
- NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient ServicesBusiness Wire
- NeuroPace (NPCE) Q3 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- NeuroPace, Inc. (NASDAQ:NPCE) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]Yahoo! Finance
NPCE
Earnings
- 11/4/25 - Beat
NPCE
Sec Filings
- 12/4/25 - Form 4
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- NPCE's page on the SEC website